Barry Ressler

Founder, President, CEO

Mr. Ressler founded STAR Associates, Inc., (www.star-assoc.com) in1994 to provide strategic advisory and project funding services for early stage industrial process and therapeutic/diagnostic technology companies.

Mr. Ressler is also the Chairman and Chief Executive Officer of the International Space Medicine Consortium (ISMC), www.ISMCinc.com, an independent and collaborative entity, founded as a Delaware Corporation to enhance the knowledge of Space Medicine and to develop diagnostic and therapeutic protocols for the unmet challenges of Micro-G and interplanetary travel helping space crews and space-faring travelers to work and live in extra-terrestrial environments. ISMC will advance the development and state of the art of a new interactive, multi-sensorial and emotional 3-D Human Persona to communicate in tele-medicine, training support, and as a companion for space travelers.

Mr. Ressler is also the founder and Chairman of the Board of Directors of EP Therapeutics, Inc. a bio-pharmaceutical company engaged in the development of a revolutionary new class of therapeutics as safer, alternative treatments for human cancers by eliminating the need for chemotherapy or radiation treatment protocols.

In 1994, Mr. Ressler co-founded, Triton Thalassic Technologies, Inc., and served as the Chief Executive Officer and Chairman of the Board. The company (T3i), is engaged in the non-chemical pathogen inactivation of blood products; photo-activation of therapeutic compounds and the treatment and control of micro-organism contaminated fluids for the industrial, food packaging, beverage, healthcare and pharmaceutical industries.

From 1975 to December 1993 he served as Chief Executive Officer and Chairman of the Board of Universal Voltronics Corporation (UVC), a public company (NASDAQ and AMEX) that developed high-voltage Pulse Power products for scientific research, defense, alternative energy sources, medical diagnostics/therapeutics and for industrial applications. In March 1990, UVC became a public subsidiary of Thermo Electron Corp, now Thermo Fisher Scientific.

Mr. Ressler serves on the Board of Directors of Forever Identity Inc. (www.foreveridentity.com), a Delaware Corporation that has developed and patented three distinct products to create and preserve identity, biography, memory, personality, and physical aspects to allow interaction with future generations. FOREVER Identity combines artificial intelligence, decision, ethical and moral engines, semantic and ontology experts to provide cutting-edge products space industry diagnostics, historic figure preservation. Education (STEM) and telemedicine applications.

Mr. Ressler served on the Board of Directors of StemCyte Inc., a global company engaged in Public and Private Umbilical Cord Blood Banking operations and advanced stem cell therapeutics for spinal cord injury, stroke, diabetes, thalassemia and Leukemia.

From 1994 to 2007 Mr. Ressler served as a member of the Board of Directors and Chairman of the of Corporate Governance Committee of JMAR Technologies Inc. (NASDAQ JMAR) the originator of Collimated Plasma Lithography and products for the public and private sectors based on its proprietary "Britelight(TM)" laser light source and homeland security, for the detection of explosives, toxic gases (nerve and blister agents), and pollutant detection.

From 1996 to 2004 Mr. Ressler has also served as a member of the Nauticos Corp. Sciences Business and Technology Advisory Board. Nauticos Corp. developed advanced side scan sonar, ROV and research protocols used in the discovery of historic and contemporary sunken vessels. Mr. Ressler has also served on the scientific advisory board of the University of Connecticut Biotechnology center.

Mr. Ressler is the inventor of 7 patents in the field of monochromatic UV sterilization of industrial fluids, blood products, injectables, ophthalmic healthcare packaged products and Parenteral Drug Delivery IV/Renal Bag technology and food/beverage process applications. Mr. Ressler is an invited speaker at the Parenteral Drug Association and to the FDA for Aseptic and Advanced Sterilization Technologies and to the United Nations in Geneva for the use of Artificial Intelligence for Medicine.